Immunome Inc’s recent filing unveils that its President and CEO SIEGALL CLAY B acquired Company’s shares for reported $1.16 million on Jan 31 ’25. In the deal valued at $7.75 per share,150,000 shares were bought. As a result of this transaction, SIEGALL CLAY B now holds 669,636 shares worth roughly $6.26 million.
Then, SIEGALL CLAY B bought 66,057 shares, generating $630,263 in total proceeds. Upon buying the shares at $9.54, the President and CEO now owns 485,693 shares.
Before that, SIEGALL CLAY B bought 33,943 shares. Immunome Inc shares valued at $331,918 were divested by the President and CEO at a price of $9.78 per share. As a result of the transaction, SIEGALL CLAY B now holds 519,636 shares, worth roughly $4.86 million.
Stephens initiated its Immunome Inc [IMNM] rating to an Overweight in a research note published on November 08, 2024; the price target was $30. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in late May with a ‘”an Overweight”‘ rating. JP Morgan began covering IMNM with “an Overweight” recommendation on April 30, 2024. Guggenheim started covering the stock on April 15, 2024. It rated IMNM as “a Buy”.
Price Performance Review of IMNM
On Friday, Immunome Inc [NASDAQ:IMNM] saw its stock fall -1.79% to $9.35. Over the last five days, the stock has lost -10.10%. Immunome Inc shares have fallen nearly -11.96% since the year began. Nevertheless, the stocks have fallen -57.52% over the past one year. While a 52-week high of $30.96 was reached on 02/10/25, a 52-week low of $8.97 was recorded on 01/29/25. SMA at 50 days reached $10.75, while 200 days put it at $12.87.
Levels Of Support And Resistance For IMNM Stock
The 24-hour chart illustrates a support level at 9.09, which if violated will result in even more drops to 8.83. On the upside, there is a resistance level at 9.73. A further resistance level may holdings at 10.11. The Relative Strength Index (RSI) on the 14-day chart is 39.31, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.82, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.67%. Stochastics %K at 7.24% indicates the stock is a buying.
The most recent change occurred on January 29, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
